OR WAIT null SECS
The new facility also provides a plan for scalable product production processes that can potentially be replicated by Vaxxas domestically and globally.
Vaxxas, a clinical-stage biotechnology company, announced the opening of its first manufacturing facility in Brisbane, Queensland, on June 19, 2023. The biomedical facility is intended to be the company’s global headquarters and will support the scale-up of its operations to produce high-density microarray patch (HD-MAP) vaccines for future late-stage clinical trials and first commercial products, according to a press release.
“This world-renowned technology has the potential to play a vital role in pandemic-preparedness because it allows vaccines to be deployed quickly and easily to our communities,” said Steven Miles, Queensland Deputy Premier, in a press release.
According to the press release, Vaxxas’s HD-MAP technology platform “utilizes an ultra-high-density array of projections applied to the skin as a patch sitting inside a small applicator device. When applied to the skin, the patch delivers vaccine to the abundant immune cells immediately below the skin surface.”
The proprietary HD-MAP technology platform from Vaxxas can improve vaccination by creating vaccine products that are easy to use and are stable at room temperature, which reduces the complexities and costs associated with refrigerated distribution required for many existing vaccines.
“The Vaxxas Biomedical Facility represents a new and exciting chapter for our company, as it is foundational for our next phase of growth. With the support of the Queensland State and Australian Federal Governments, the Vaxxas Biomedical Facility will firmly position Australia at the forefront of vaccine technology innovation,” said David Hoey, chief executive officer at Vaxxas, in a press release. “The site will significantly increase our manufacturing capacity, creating new local, skilled jobs, while enabling Vaxxas to progress through late-stage clinical trials that will bring our first commercial vaccine products to the market.”
The new facility also provides a plan for scalable product production processes that can potentially be replicated by Vaxxas domestically and globally, according to the press release.